
If you are into giving gifts possibly consider giving yourself the gift of wellness by seeing a nutritionist before the year is over or to begin 2018 in a good direction.

If you are into giving gifts possibly consider giving yourself the gift of wellness by seeing a nutritionist before the year is over or to begin 2018 in a good direction.

While patients with chronic lymphocytic leukemia (CLL) tend to have long life expectancies, with many prescribed to a “watch-and-wait” approach, a recent study by the Cancer Support Community (CSC) found that more than half of patients living with the disease reported that having CLL affects their viewpoints regarding their life expectancy.

Not all employees with cancer get paid leave, but those who did saw better health and financial outcomes.

Malnutrition is common in patients with cancer, but there are steps that can be taken to avoid it.

A four-drug combination, including Tecentriq (atezolizumab), Avastin (bevacizumab), carboplatin and paclitaxel, delayed progression or death by 38 percent in patients with advanced non-squamous non–small cell lung cancer (NSCLC), compared to those who were treated with Avastin alone.

Approximately 420,000 Americans are adult survivors of childhood cancer, and these individuals may be twice as likely to have high blood pressure, also known as hypertension, according to researchers at St. Jude Children’s Research Hospital.

Of course, there was sadness, but more than anything there was appreciation for my own life and the people close to me. I feel gratitude for still being here, having an excellent quality of life and for the warning cancer gives.

The FDA has approved a novel breast-specific stereotactic body radiotherapy (SBRT) device known as GammaPod as a treatment for patients with breast cancer, based on findings from a 17-patient study.

After breast cancer surgery and lymph node removal, I developed lymphedema, a painful, lifelong condition. This medical problem is often misunderstood but is it my place to help bring awareness? One survivor speaks out.

Although ROS1 mutations are quite rare in patients with non-small cell lung cancer (NSCLC), testing for the mutation in all who have the disease is important, as it can play a vital role in determining a treatment plan.

Imfinzi (durvalumab), a PD-L1 inhibitor, is being reviewed for a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) for the treatment of patients with stage 3, unresectable non-small cell lung cancer (NSCLC). The sBLA is in light of positive progression-free survival (PFS) results from the phase 3 PACIFIC trial.

A very light hearted look at a serious problem.

The Food and Drug Administration (FDA) has granted a priority review to a supplemental new drug application (sNDA) for the use of Tafinlar (dabrafenib) combined with Mekinist (trametinib) as an adjuvant treatment for patients with BRAFV600E– or V600K–positive stage 3 melanoma following complete resection.

The liver cancer treatment field has remained stagnant for years, but new agents are destined to enter the field in the near future, Ghassan K. Abou-Alfa, M.D., says.










Breast cancer and melanoma survivor shares coping strategies for the holidays.

The FDA has granted a priority review to a new drug application (NDA) for apalutamide (ARN-509) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.

Blue Faery, the Adrienne Wilson Liver Cancer Association, is a nonprofit corporation founded in 2002, with the intent to prevent, treat and cure primary liver cancer – particularly HCC – through research, education and advocacy. Its name, inspired by Adrienne, has a unique background.

How often do you pause for reflection?

The FDA has approved Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence, based on findings from the APHINITY trial.

The FDA has approved Opdivo (nivolumab) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease, based on findings from the phase 3 CheckMate-238 trial.